Kathrin Heinrich(@heinrich_kat) 's Twitter Profile Photo

Our case of a patient with with MSI & BRAF fusion is now out in JCO Precision Oncology

ascopubs.org/doi/10.1200/PO…

👉BRAF fusion as an alternative route to MSI
👉excellent & long lasting response to

OncoAlert 🚨 Ben Westphalen 💜

Our case of a patient with #pancreaticcancer with MSI & BRAF fusion is now out in @JCOPO_ASCO 

ascopubs.org/doi/10.1200/PO… 

👉BRAF fusion as an alternative route to MSI
👉excellent & long lasting response to #immunotherapy

@OncoAlert 🚨 @BenWestphalen #PancSM 💜 #PrecisionMedicine
account_circle
Ian Demsky(@IanDemsky) 's Twitter Profile Photo

It was a pleasure and a privilege to write about new research, just out in Science Magazine, from dana_peer, Lowe Lab, Cassandra Burdziak & Direna Alonso-Curbelo that provides an in-depth analysis of the earliest beginnings of .
mskcc.org/news/expansion…

account_circle
Michael Yan, MD MPH(@MichaelYanMD) 's Twitter Profile Photo

First randomized evidence supporting PFS benefit of MDT for OM-pancreatic cancer in P2-EXTEND trial. OS no different, but do other endpoints matter (e.g. maintenance of earlier line systemic therapy)?

First randomized evidence supporting PFS benefit of MDT for OM-pancreatic cancer in P2-EXTEND trial. OS no different, but do other endpoints matter (e.g. maintenance of earlier line systemic therapy)? #GI24 #pancsm
account_circle
Terry Williams(@TeWilliamsMD) 's Twitter Profile Photo

Congrats to Adam Wolfe, MD, PhD, Tiantian Cui MD, PhD, and the rest of the stellar team for the Science Advances publication on nutrient scavenging in . 👏
The work uncovers a pivotal role for caveolae-mediated endocytosis (CME) in fueling growth.

Congrats to @AdamWolfeMDPhD, @cui_tiantian, and the rest of the stellar team for the @ScienceAdvances publication on nutrient scavenging in #pancreaticcancer. 👏
The work uncovers a pivotal role for caveolae-mediated endocytosis (CME) in fueling #PDAC growth.   #pancsm #gism
account_circle
Kathrin Heinrich(@heinrich_kat) 's Twitter Profile Photo

Now live at - Upper GI Poster discussion.

First data of the 3-Arm Arbeitsgemeinschaft Internistische Onkologie - AIO FOOTPATH trial in metastatic presented by Ben Westphalen .

In FOOTPATH, sequential application of NAPOLI/FOLFOX was found to be effective and well tolerated.

OncoAlert 🚨

Now live at #ASCO23 - Upper GI Poster discussion. 

First data of the 3-Arm @AIO_Onkologie FOOTPATH trial in metastatic #pancsm presented by @BenWestphalen .

In FOOTPATH, sequential application of NAPOLI/FOLFOX was found to be effective and well tolerated.   

@OncoAlert 🚨
account_circle
Jun Gong(@jgong15) 's Twitter Profile Photo

Eileen M O’Reilly dawn of inh’s beyond , young onset w/signal of KRAS WT, WT exquisitely targetable, & building on maintenance concept in

Now at Cancer at Cedars-Sinai 4th Annual GI Tumor conf cedars.cloud-cme.com/gicancercme OncoAlert

@EileenMOReilly dawn of #KRAS inh’s beyond #G12C, young onset #PDAC w/signal of KRAS WT, #KRAS WT #pancsm exquisitely targetable, & building on #POLO maintenance concept in #DDR #PancreaticCancer 

Now at @CSCancerCenter 4th Annual GI Tumor conf cedars.cloud-cme.com/gicancercme @OncoAlert
account_circle
4PCAN_Project(@4PCAN_Project) 's Twitter Profile Photo

🔍 This , let's shine a light on the need for increased awareness. Studies show smoking 🚭, alcohol consumption 🍷, and obesity 🍔 are potential risk factors. Let's spread knowledge and encourage preventive actions against pancreatic cancer.

🔍 This #PancreaticCancerAwarenessMonth, let's shine a light on the need for increased awareness. Studies show smoking 🚭, alcohol consumption 🍷, and obesity 🍔 are potential risk factors. Let's spread knowledge and encourage preventive actions against pancreatic cancer. #pancsm
account_circle
Krishan Jethwa(@KrishanJethwa) 's Twitter Profile Photo

@laurenhenke presenting a brilliant talk on “state of the art” radiotherapy techniques and novel indications for PDAC 👏🏼👏🏼👏🏼

We’ve come a long way and looking forward to collaborations and future studies to help our patients in this tremendous area of need!

@laurenhenke presenting a brilliant talk on “state of the art” radiotherapy techniques and novel indications for PDAC 👏🏼👏🏼👏🏼

We’ve come a long way and looking forward to collaborations and future studies to help our patients in this tremendous area of need!
#ASCO23 #pancsm
account_circle
Brandon Huffman, MD(@BHuffmanMD) 's Twitter Profile Photo

Dose modifications of gem/nab-pac were so common in this 2nd line trial. For instance, in the 3rd cycle, 82% of remaining patients had a chemotherapy dose reduction (20/38) and/or schedule modification (22/38).

jamanetwork.com/journals/jaman…

Dose modifications of gem/nab-pac were so common in this 2nd line #PDAC trial. For instance, in the 3rd cycle, 82% of remaining patients had a chemotherapy dose reduction (20/38) and/or schedule modification (22/38). #PancreaticCancer #Pancsm

jamanetwork.com/journals/jaman…
account_circle
Daniel Haldar(@DanielHaldarMD) 's Twitter Profile Photo

Pleasure to share our Johns Hopkins Kimmel Cancer Center results from an interception trial studying an off-the-shelf mutant KRAS vaccine in pts at high risk of developing PDAC at

Pleasure to share our @hopkinskimmel results from an interception trial studying an off-the-shelf mutant KRAS vaccine in pts at high risk of developing PDAC at #AACR24 #pancsm
account_circle
Oncology Data Advisor(@OncData) 's Twitter Profile Photo

What do you think about this week's approval of liposome/oxaliplatin/fluorouracil/leucovorin ( ) for first-line treatment of metastatic adenocarcinoma?

Share your opinions in the comments!
Tom Abrams

Read more: oncdata.com/news/irinoteca…

What do you think about this week's #FDA approval of  #irinotecan liposome/oxaliplatin/fluorouracil/leucovorin (#NALIRIFOX) for first-line treatment of metastatic #pancreatic adenocarcinoma?

Share your opinions in the comments!
@onctom #pancsm

Read more: oncdata.com/news/irinoteca…
account_circle
OncLive.com(@OncLive) 's Twitter Profile Photo

Neoadjuvant CAN-2409 plus valacyclovir and chemoradiation, followed by resection, elicited a sustained survival benefit vs the SOC alone in a phase 2 study of patients with borderline resectable PDAC. onclive.com/view/can-2409-…

Neoadjuvant CAN-2409 plus valacyclovir and chemoradiation, followed by resection, elicited a sustained survival benefit vs the SOC alone in a phase 2 study of patients with borderline resectable PDAC. #pancsm #oncology onclive.com/view/can-2409-…
account_circle